Lilly acts against cosmetic use of Zepbound and rise in fakes

8 March 2024
lilly_big

With demand for GLP-1 agonists  outstripping supply, Zepbound (tirzepatide) developer Eli Lilly (NYSE: LLY) has issued a warning against resorting to counterfeits.

In a statement, the firm said it was “deeply concerned” that compounding pharmacies or counterfeiters could be offering products which are fraudulently claimed to be Zepbound, an obesity med with impressive and clinically-proven weight loss credentials.

Also marketed as Mounjaro for diabetes, the product is competing with market leader Wegovy (semaglutide), from Novo Nordisk (NOV: N), which has also seen extremely high demand.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical